Tomoki Nakamura1, Katsuyuki Kusuzaki2, Takao Matsubara3, Akihiko Matsumine3, Kunihiro Asanuma3, Haruhiko Satonaka4, Atsumasa Uchida3, Akihiro Sudo3. 1. Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Mie, Japan tomoki66@clin.medic.mie-u.ac.jp. 2. Department of Orthopaedic Surgery, Kujyo Hospital, Kyoto, Japan. 3. Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Mie, Japan. 4. Department of Orthopaedic Surgery, Ise Municipal General Hospital, Ise, Japan.
Abstract
AIM: We undertook studies to determine the lethal dose 50 (LD50) of acridine orange (AO) using mice in order to confirm the safety of intravenous administration of AO. MATERIALS AND METHODS: We used 40 mice and AO was administered once intravenously. General behavior and mortality were continuously observed for 14 days. At the end of the experiment, all animals were sacrificed for subsequent studies. RESULTS: The LD50 for AO in male and female mice was determined to be 32 mg/kg and 36 mg/kg, respectively. Histopathological abnormalities were observed in only one mouse which died three days after the administration of AO. The other nine mice which died immediately after the administration of AO had no pathological findings in major organs. CONCLUSION: The clinical use of AO can be kept at 1.0 mg/kg or below and, therefore, intravenous administration of AO might be safe for use as cancer therapy.
AIM: We undertook studies to determine the lethal dose 50 (LD50) of acridine orange (AO) using mice in order to confirm the safety of intravenous administration of AO. MATERIALS AND METHODS: We used 40 mice and AO was administered once intravenously. General behavior and mortality were continuously observed for 14 days. At the end of the experiment, all animals were sacrificed for subsequent studies. RESULTS: The LD50 for AO in male and female mice was determined to be 32 mg/kg and 36 mg/kg, respectively. Histopathological abnormalities were observed in only one mouse which died three days after the administration of AO. The other nine mice which died immediately after the administration of AO had no pathological findings in major organs. CONCLUSION: The clinical use of AO can be kept at 1.0 mg/kg or below and, therefore, intravenous administration of AO might be safe for use as cancer therapy.
Authors: Vadim A Byvaltsev; Liudmila A Bardonova; Naomi R Onaka; Roman A Polkin; Sergey V Ochkal; Valerij V Shepelev; Marat A Aliyev; Alexander A Potapov Journal: Front Oncol Date: 2019-09-24 Impact factor: 6.244